NASDAQ$WGS
GeneDx Holdings Corp · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
GeneDx reported Q1 2026 total revenue of $102.3M and a net loss of $63.3M, with diluted loss per share of $2.16.
GeneDx (WGS) generated total revenue of $102.3 million (+17% YoY), driven by diagnostic test revenue of $101.3 million. Gross profit was $68.2 million, but R&D and SG&A of $94.4 million plus a $31.3 million impairment produced a loss from operations of $57.5 million. Net loss widened to $63.3 million, or $2.16 per share, from $6.5 million a year ago as commercial and clinical investments scaled.
- Total revenue $102.3M (+17% YoY); diagnostic tests $101.3M.
- Gross profit $68.2M; impairment loss $31.3M in the quarter.
- Loss from operations $(57.5)M; net loss $(63.3)M.
- Diluted loss per share $(2.16) vs. $(0.23) prior year.
- R&D and SG&A growth reflects commercial expansion of genomic testing.
Headline financials
Revenue & EPS history
GeneDx Holdings Corp · Revenue · Quarterly
$102M
Forward guidance
Management highlights test volume growth and payer coverage expansion; no formal FY revenue or EPS targets in the 10-Q.
Tailwinds
- Diagnostic revenue growth and strong gross margin dollars.
- Higher test volumes support scale economics.
Headwinds
- Operating losses widened on R&D, SG&A, and impairment.
- Cash burn and path to profitability depend on reimbursement trends.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q1 2026
-0.2%
Avg return
Earnings day
-7.5%
Avg return
5 days after
-10.6%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+49.9%
Q3 2024
Best reaction
-42.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -37.6% | -18.8% | |
| Q4 2025 | +6.1% | -2.9% | -18.4% | |
| Q3 2025 | +5.2% | +4.8% | +26.7% | |
| Q1 2025 | -42.8% | -43.4% | -39.1% | |
| Q3 2024 | +49.9% | +38.7% | +41.7% | |
| Q2 2024 | -10.6% | -10.7% | -3.6% | |
| Q1 2024 | -0.7% | +77.4% | +90.9% | |
| Q3 2023 | -1.1% | -20.7% | -2.2% | |
| Q2 2023 | -0.6% | -21.2% | -34.1% | |
| Q1 2023 | -5.6% | -22.2% | -24.3% | |
| Q3 2022 | -12.2% | -39.0% | -70.8% | |
| Q2 2022 | -1.2% | -51.0% | -58.8% | |
| Q1 2022 | +10.3% | +32.1% | +1.9% | |
| Q3 2021 | -2.5% | -9.2% | -39.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro